Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP993155priorityCriticalpatent/ECSP993155A/en
Publication of ECSP993155ApublicationCriticalpatent/ECSP993155A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se describen compuestos quimicos que comprenden fosforamidatos de nucleósidos su preparción y su uso terapéutico en el tratamiento de infecciones virtales, en particular HIV y HBV. Los compuestos contienen un resto de análogo de nucleósido adenina sustituido que comprende 2-amino-6-(ciclopropilamino)-9H-purin-9-ilo. Los compuestos presentan actividad antiviral y estabilidad frente a los ácidos. Se incluyen las sales y ésteres de los fosforamidatos. Un compuesto representativo es el 5¿-[fenil-(metoxi-L-alaninil]-fosforamidato de (1S, 4R)-4-[2-amino-6-(ciclopropilamino)-9H-purin-9-il]-2-ciclopentano-1-metanol.Chemical compounds comprising nucleoside phosphoramidates, their preparation and their therapeutic use in the treatment of viral infections, in particular HIV and HBV, are described. The compounds contain a substituted adenine nucleoside analog residue comprising 2-amino-6- (cyclopropylamino) -9H-purin-9-yl. The compounds have antiviral activity and stability against acids. Salts and esters of phosphoramidates are included. A representative compound is (1S, 4R) -4- [2-amino-6- (cyclopropylamino) -9H-purin-9-yl] -2-5-- [phenyl- (methoxy-L-alaninyl] -phosphoramidate. -cyclocyclopentane-1-methanol.
Piliostigma thonningii extracts, their use and Piliostigma thonningii extracts, their use and formulations containing them Formulations containing them